# Renalytix

**Company Overview** 

January 2022



#### Disclaimer

This Presentation is confidential and is being supplied to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. Subject to certain exceptions, this Presentation is not for distribution in the United States, Australia, Canada or Japan or any other jurisdiction where its distribution may constitute a violation of the laws of such jurisdiction.

The information contained in this confidential document ("Presentation") has been prepared by Renalytix plc (the "Company") solely for your information and use at a presentation for the purposes of providing background information on the Company, its business and the industry in which it operates and neither this Presentation, nor the information contained in it should be considered a recommendation by the Company or any of its shareholders, directors, officers, agents, employees or advisers in relation to any purchase of the Company's securities, including any purchase of or subscription for any shares (or securities convertible into shares) in the capital of the Company. This Presentation has not been fully verified and is subject to material updating, revision and further amendment. Any person who receives this Presentation should not rely or act upon it. This Presentation should not be re-distributed, re-published, reproduced or disclosed by recipients, in whole or in part.

While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefor is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, including those described in the Company's filings with the Securities and Exchange Commission and actual results and developments may differ materially from those expressed or implied by these statements and past performance is no guarantee of future performance. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, revenue generation, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential" "predict," "project," "should," "target," or "will" or the negative of these terms or other similar expressions.

The Presentation also contains estimates, projections and other information concerning our industry, our business and the markets for KidneyIntelX and any other products we may develop in the future. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in the information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research, surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Presentation, their estimates, in particular as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors. Market data and industry information used throughout this Presentation are based on management's knowledge of the industry and the good faith estimates of management. We also relied, to the extent available, upon management's review of independent industry surveys and publications and other publicly available information prepared by a number of third-party sources. All of the market data and industry information used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Although we believe these sources are reliable, we cannot guarantee the accuracy or completeness of this information, which is derived in part from management's estimates and beliefs, are inherently uncertain and imprecise.

This Presentation is only addressed to and directed at (i) persons who are outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (iii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and/or (iv) any other persons to whom this presentation may otherwise lawfully be communicated without contravention of section 21 of the Financial Services and Markets Act 2000 or to whom it may otherwise lawfully be distributed (all such persons together being referred to as "relevant persons"). This presentation may not be acted on or relied on by persons who are not relevant persons. Any investment activity to which this presentation relates is available only (i) in the United Kingdom, to relevant persons who are qualified investors within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) ("Qualified Investors") and (ii) in any member state of the European Economic Area ("EEA"), to Qualified Investors, and will be engaged in only with such persons. This presentation must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons and Qualified Investors, and (ii) in any member state of the EEA, by persons who are not Qualified Investors.

By participating in and/or accepting delivery of this Presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer.

## Leadership Team



James McCullough Co-Founder, CEO

Prior experience Exosome Diagnostics Co-Founder, CEO

Liquid biopsy spin-out Harvard/MGH (2008) Raised >\$50m Equity Capital (2008 – 2014)

\$575m Bio-Techne acquisition (2018)

**Renwick Capital** 

Managing Partner (Since 2014)



Tom McLain President

Prior experience

**Exosome Diagnostics** 

General Manager, CEO
Built commercial, operational capabilities to
drive national product launch (2015-2016)
Accelerated Medicare/ private payer coverage

\$575m Bio-Techne acquisition (2018)

Vermillion

President & CEO

Recapitalized company (2013); Positioned novel ovarian cancer diagnostic for clinicians, regulators, payers and patients (2013-2014)



Fergus Fleming
Chief Technology Officer

Prior experience EKF Diagnostics Senior Project Manger (2013-2018)

**FF Consulting Limited** 

Managing Director
Provided Product Development and
Commercialization support to
Medical Devices and Diagnostics

companies since June 2013

Diagnostics

'П



O. James Sterling
Chief Financial Officer

Prior experience
Renwick Capital
Managing Partner (Since 2015)

Brock Capital Group
Managing Director

Booz Allen (now Strategy&)
Management Consultant



exosomed.

VERMILLION°



Michael Donovan,
PhD, MD
Chief Medical Officer &
Laboratory Medical Director

Prior experience Mount Sinai

Professor of Experimental Pathology and Director of the Biorepository and Pathology

**Vigilant Biosciences** 

Chief Clinical Officer Exosome Diagnostics Chief Medical Officer







Steven Coca, DO Co-Founder

Prior experience Mount Sinai Associate Professor of Medicine -Nephrology



## **Investment Highlights**

#### **3 Years Since Operations Began**

KidneyIntelX<sup>™</sup> is first validated advanced prognostic in early-stage kidney disease

Integrated directly into healthcare system EHRs

- Medicare National Price Award at \$950
- GSA Coverage Award at \$950
- AMA Distinct CPT Code
- FDA Breakthrough Device
- New York State Department of Health
- Multiple Private Payors including first regional Blue Cross Blue Shield plans

2022 Revenue Growth from

- Health System Partner Test Sales
- Strategic Activities

#### **Growth Ecosystem**

**Health Systems** 

UNIVERSITY







**ST. JOSEPH'S** 

Strategics



Singing River Foundation



Payor Lead Model



Education





#### **Anticipated Calendar** 2022 Milestones

>10M insured lives in 2022

- US Federal Government (GSA)
- Medicare
- Medicaid
- Expanding Private Payors

FDA de Novo Marketing Authorization

Multiple Hospital System Partnerships

Real World Evidence data read-outs

VA Health System Sales Force Expansion

**Expanded Testing Agreements** 

### Recent Events 3 Months



Health system partnership with Singing River Health System





Health system partnership with St. Josephs Health System





KidneyIntelX testing initiated with Wake Forest Baptist Health System





American Diabetes Association national care model/education program





Positive study results on KidneyIntelX therapeutic monitoring published





Direct sales force deployment in VA Medical system



## Unprecedented Medical Need and Market Opportunity

## The Numbers

#### 37 million

Americans currently estimated with CKD

#### 850 million

people estimated with CKD worldwide

#### >100,000

Americans begin hemodialysis from kidney failure / year

#### The Healthcare Challenge

#### ~60 million

adults in the U.S. expected to be diagnosed with diabetes by 2060

#### 100,000

Americans waiting for kidney transplant;
13 die every day

#### 63%

of patients initiate dialysis in an unplanned fashion ("crash")

#### **The Cost**

#### >\$120 billion

or 20% of Medicare budget spent per year for treatment of CKD (incl. ESKD)

#### \$36 billion

or 6.7% of Medicare budget spent per year for treatment for kidney failure to care for <1% of the covered population

#### \$1.1 billion<sup>1</sup>

can be saved over 5 years per 100,000 early-stage DKD patients receiving KidneyIntelX informed care 2022 KidneyIntelX™ is expected to have insurance payment for

>10M lives

Source: McCullough, KP, et al. J Am Soc Nephrol. 2019;30:127–135 ¹https://www.tandfonline.com/doi/full/10.1080/13696998.2021.1960714 ²Assumes Medicare payment established in calendar 2022


## Urgent and Immediate Need to Clarify Who Has Progressive Kidney Disease

1 in 5
will rapidly progress
to kidney failure

Who Is It?




## Powerful and Clear Prediction for Improved Kidney Health




Risk score



algorithm





## Integrated Health System Model Drives Utility and Care Quality

#### **Hospital Care Coordinator**

- Identifies Eligible Patients in System for risk assessment
- Pre-pends KidneyIntelX™



#### **Primary Care Visit**

- KidneyIntelX score automatically transmitted to PCP in the EHR
- Care Navigation follows



#### **Care Team Follow-up**

Dietician / Pharmacist / Clinical Coordinator

#### **Care Management**

- Patient office and telephone follow up
- Detailed chart reviews
- Pharmacy management
- Education on kidney disease
- Activate Specialist Referral

#### **Process Outcomes**

- Optimized pharmacy management including SGLT2i / RAASi / finerenone
- Appropriate referrals
- Lifestyle / dietary changes

#### **Driving & Tracking Outcomes**

- Maintain Kidney Health
- Reduce Kidney Decline
- Reduce Crash Dialysis Starts
- Reduce Hospitalizations
- Optimize Care Resources

## Integrated Model Enables Significant Value for Renalytix



Electronic market access to large body of treating physicians



Population health engagement to educate/support PCP base



Long-term competitive barriers to market entry



Cost savings enables value based care arrangements with payers



Continuous data for broad payment, RWE, product improvements




Focus on compliance and quality control enables scale







### Growth Opportunities in Multiple Market Segments



Note: Addressable market figures are estimates based on publicly available information and generally recognized population disease percentages, and may include current and future expected KidneyIntelX™ product versions and indicated uses

## Health Economics – A Major Driver to Adoption

## **Slowed Progression** through CKD Stages

Better risk assessment & patient awareness allows intervention to modify DKD progression

## **Positive Returns and Cost Savings for Health Insurers**

KidneyIntelX<sup>™</sup> could deliver cost savings of up to \$1.1 billion over five years per 100,000 patients with DKD<sup>1</sup>



# Delayed or Prevented Dialysis & Transplants Early intervention can delay or p

Early intervention can delay or prevent dialysis and kidney transplant events

## Fewer ER Events & Dialysis Crashes

Advanced warning of acute events allows for planned dialysis

<sup>&</sup>lt;sup>1</sup> https://www.tandfonline.com/doi/full/10.1080/13696998.2021.1960714

#### Calendar 2022 Milestone Events



20 health system partnerships target



Expanded payment w/Medicare & private insurance



FDA de Novo Marketing Authorization



Strategic partnerships